Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment

• Status: Completed
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the effect of renal function impairment on the single dose pharmacokinetics of Daclatasvir.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• Meet renal function criteria in one of four categories

Exclusion Criteria:

• Unstable or uncontrolled medical conditions